Drug Profile
Research programme: intranasal interferon beta - Neurelis/Johns Hopkins/Nerveda
Alternative Names: Non-injectable interferon beta - Neurelis/Johns Hopkins/NervedaLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Aegis Therapeutics; Nerveda
- Developer Aegis Therapeutics; Johns Hopkins University; Nerveda
- Class Antineoplastics; Antivirals; Interferons; Skin disorder therapies
- Mechanism of Action Immunostimulants; Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 01 Aug 2016 No development reported - Preclinical for Multiple sclerosis in USA (Intranasal)
- 12 Jan 2009 Preclinical trials in Multiple sclerosis in USA (Intranasal)